Multivariable analysis of OS
| . | Hazard ratio . | (95% CI) . | P . |
|---|---|---|---|
| Patient sex: female vs male | .80 | (0.67-0.96) | .017 |
| Age at diagnosis* | .12 | (1.02-1.24) | .023 |
| Lower-risk patients | |||
| Td AML | .14 | (3.63-7.28) | <.001 |
| Td allo-HCT (without AML): 0-2 y | .19 | (2.30-4.42) | <.001 |
| Td allo-HCT (without AML): >2 y | .98 | (0.58-1.64) | .924 |
| Td allo-HCT (after AML): 0-2 y | .89 | (0.53-1.50) | .675 |
| Td allo-HCT (after AML): 2+ y | .20 | (0.0.07-0.56) | .002 |
| Higher-risk patients | |||
| Td AML | .68 | (2.74-4.92) | <.001 |
| Td allo-HCT (without AML): 0-2 y | .46 | (1.09-1.96) | .012 |
| Td allo-HCT (without AML): 2+ y | .60 | (0.34-1.08) | .089 |
| Td allo-HCT (after AML): 0-2 y | .45 | (0.28-0.73) | .001 |
| Td allo-HCT (after AML): 2+ y | .08 | (0.0.02-0.33) | .001 |
| . | Hazard ratio . | (95% CI) . | P . |
|---|---|---|---|
| Patient sex: female vs male | .80 | (0.67-0.96) | .017 |
| Age at diagnosis* | .12 | (1.02-1.24) | .023 |
| Lower-risk patients | |||
| Td AML | .14 | (3.63-7.28) | <.001 |
| Td allo-HCT (without AML): 0-2 y | .19 | (2.30-4.42) | <.001 |
| Td allo-HCT (without AML): >2 y | .98 | (0.58-1.64) | .924 |
| Td allo-HCT (after AML): 0-2 y | .89 | (0.53-1.50) | .675 |
| Td allo-HCT (after AML): 2+ y | .20 | (0.0.07-0.56) | .002 |
| Higher-risk patients | |||
| Td AML | .68 | (2.74-4.92) | <.001 |
| Td allo-HCT (without AML): 0-2 y | .46 | (1.09-1.96) | .012 |
| Td allo-HCT (without AML): 2+ y | .60 | (0.34-1.08) | .089 |
| Td allo-HCT (after AML): 0-2 y | .45 | (0.28-0.73) | .001 |
| Td allo-HCT (after AML): 2+ y | .08 | (0.0.02-0.33) | .001 |
Effect estimates from multivariable Cox proportional hazards model allowing different baseline hazards for lower and higher CPSS risk groups. The model was adjusted for age and sex. Transformation to AML and transplantation were included as time-dependent (Td) covariates. To overcome violations of the proportional hazards assumption, the effect of allo-HCT was split into an average short-/midterm effect covering the first 2 years after transplantation and an average long-term effect covering the period beyond 2 years after allo-HCT. The latter is estimated in patients who are alive at 2 years since allo-HCT
Unit 10 years